IP Library Granted Patent US 11,753,449
Granted Patent B2
US 11,753,449 · App. 16/649,879 · Granted Sep 12, 2023

Immunoglobulin binding protein, and affinity support using same

Inventors: Jun-ichi Yasuoka (Minato-ku, JP); Kiichi Yoshimura (Minato-ku, JP)
Assignees: JSR CORPORATION; JSR Life Sciences Corporation; JSR Life Sciences, LLC; JSR Micro N.V.
C07K14/195C07K1/22C07K14/001C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,753,449
App. No.
16/649,879
Granted
Sep 12, 2023
Kind
B2
Abstract

Provided are a protein L-derived immunoglobulin binding protein having an increased alkali tolerance, and an affinity support using the same. Disclosed are an immunoglobulin binding protein comprising at least one mutant of an immunoglobulin binding domain, and an affinity support comprising a solid-phase support having the immunoglobulin binding protein bound thereto. A mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 85% with the sequence set forth in any one of SEQ ID NO:1 to SEQ ID NO:9 and a predetermined mutation, and the mutant has immunoglobulin κ chain binding activity.

Claims (22)

1. An immunoglobulin binding protein, comprising at least one mutant of an immunoglobulin binding domain,

wherein the at least one mutant of the immunoglobulin binding domain consists of an amino acid sequence having an identity of at least 95% with the sequence set forth in SEQ ID NO:9, the amino acid sequence having a substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, and

at least one of a substitution of threonine at a position corresponding to the 35th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, a substitution of asparagine at a position corresponding to the 54th-position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine, and a substitution of glutamic acid at a position corresponding to the 42nd-position of the amino acid sequence set forth in SEQ ID NO:9 with lysine, and wherein the mutant has immunoglobulin κ chain binding activity.

2. The immunoglobulin binding protein according to claim 1 , wherein the at least one mutant has the substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, and the substitution of threonine at a position corresponding to the 35th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine.

3. The immunoglobulin binding protein according to claim 1 , wherein the at least one mutant has the substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine and the substitution of asparagine at a position corresponding to the 54th-position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine.

4. The immunoglobulin binding protein according to claim 1 , wherein the at least one mutant has the substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine and the substitution of glutamic acid at a position corresponding to the 42nd-position of the amino acid sequence set forth in SEQ ID NO:9 with lysine.

5. The immunoglobulin binding protein according to claim 1 , wherein the at least one mutant has the substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, the substitution of threonine at a position corresponding to the 35th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, the substitution of asparagine at a position corresponding to the 54th-position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine, and the substitution of glutamic acid at a position corresponding to the 42th-position of the amino acid sequence set forth in SEQ ID NO:9 with lysine.

6. A polynucleotide encoding the immunoglobulin binding protein according to claim 1 .

7. A vector comprising the polynucleotide according to claim 6 .

8. A transformant comprising the vector according to claim 7 .

9. An affinity support, comprising a solid-phase support; and the immunoglobulin binding protein according to claim 1 bound to the solid-phase support.

10. A method, comprising:

isolating an antibody or a fragment thereof with the affinity support according to claim 9 .

11. A method for producing an immunoglobulin binding protein, the method comprising:

(i) expressing the immunoglobulin binding protein according to claim 1 in a transformant comprising a vector comprising a polynucleotide encoding the immunoglobulin binding protein or in a cell-free protein synthesis system, or

(ii) chemically synthesizing the immunoglobulin binding protein according to claim 1 .

12. A method for producing a mutant of an immunoglobulin binding domain, the method comprising:

introducing a mutation to a polypeptide consisting of an amino acid sequence set forth in SEQ ID NO:9 or an amino acid sequence having an identity of at least 95% therewith, the polypeptide having immunoglobulin κ chain binding activity:

wherein the mutation is a substitution of lysine at a position corresponding to the 26th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, and

at least one of a substitution of threonine at a position corresponding to the 35th-position of the amino acid sequence set forth in SEQ ID NO:9 with arginine, a substitution of asparagine at a position corresponding to the 54th-position of the amino acid sequence set forth in SEQ ID NO:9 with glutamine, and a substitution of glutamic acid at a position corresponding to the 42nd-position of the amino acid sequence set forth in SEQ ID NO:9 with lysine.

13. method for producing an affinity support, the method comprising:

immobilizing the immunoglobulin binding protein according to claim 1 on a solid-phase support.

Assignments (9)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2026
From: MBL MATERIALS CO., LTD.
To: JSR CORPORATION
Reel/Frame 074227/0181 →
CHANGE OF ADDRESS Recorded Mar 25, 2026
From: MBL MATERIALS CO., LTD.
To: MBL MATERIALS CO., LTD.
Reel/Frame 075228/0238 →
CHANGE OF NAME Recorded Mar 25, 2026
From: JSR LIFE SCIENCES CORPORATION
To: MBL MATERIALS CO., LTD.
Reel/Frame 075228/0228 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: JSR LIFE SCIENCES, LLC
To: JSR CORPORATION
Reel/Frame 074082/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2026
From: JSR MICRO NV
To: JSR CORPORATION
Reel/Frame 074082/0011 →
MERGER Recorded Sep 22, 2025
From: JSR CORPORATION
To: JICC-02 CORPORATION
Reel/Frame 072935/0152 →
CHANGE OF NAME Recorded Sep 22, 2025
From: JICC-02 CORPORATION
To: JSR CORPORATION
Reel/Frame 072326/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: JSR MICRO, INC.
To: JSR LIFE SCIENCES, LLC
Reel/Frame 057092/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2020
From: YASUOKA, JUN-ICHI; YOSHIMURA, KIICHI
To: JSR CORPORATION; JSR LIFE SCIENCES CORPORATION; JSR MICRO INC.; JSR MICRO N.V.
Reel/Frame 052197/0544 →
Priority Claims (1)
JP 2017-184158 · Sep 25, 2017 · national
Continuity (1)
Related Publication 20210163545A1 · Jun 3, 2021